| Prevention of Incontinence |
|
|
Comparatively little is known about the prevention of incontinence. For this reason the Continence Foundation joined the CONTINENCE PROMOTION COMMITTEE of the International Continence Society and the SIMON FOUNDATION FOR CONTINENCE in the USA to sponsor an international consensus conference on the subject in June 1997. The conference was made possible by an educational grant from Pharmacia Ltd. |
||
| CONSENSUS
STATEMENT PUBLISHED AFTER THE CONFERENCE LIST OF INVITED PARTICIPANTS |
||
|
CONSENSUS
STATEMENT
FIRST INTERNATIONAL CONFERENCE FOR THE PREVENTION OF INCONTINENCE DANESFIELD HOUSE U.K. JUNE 25-27 1997 |
| INTRODUCTION A: CLINICAL DEFINITION B: THE CONCEPT OF PREVENTION C: HEALTHY BLADDER HABITS D: INCONTINENCE PREVENTION BY AGE GROUP - PREVENTION IN CHILDHOOD - PREVENTION IN YOUNG ADULTS - PREVENTION IN THE MIDDLE YEARS - PREVENTION IN HEALTHY OLDER ADULTS - PREVENTION IN FRAIL OLDER ADULTS E: PROMOTING PREVENTION EDUCATION BY TARGET GROUP |
| Introduction |
| A
two day conference was convened at the Danesfield House U.K. with the
intent of creating a Consensus Statement which would guide and direct
future clinical practice and research for the Prevention of Incontinence. First conceived during discussions of the Continence Promotion Committee at the 1996 ICS (International Continence Society) meeting in Athens it was through the outstanding initiative of The Simon Foundation for Continence (USA) and The Continence Foundation (UK) that the First International Conference for the Prevention of Incontinence (P97) was realised. Forty two internationally recognised experts in the field came together to examine and critique current research. Rigorous intellectual debate followed each of the dozen presentations. The dynamic interaction and collaboration of panel, presenters and expert audience was as stimulating as it was productive. Pieces of the prevention puzzle emerged as presentations and debates progressed. This Consensus Statement is the outcome of these two days in June. Special mention is due Dr. Alan Cottenden, panel chair, and conference co-chairs Cheryle Gartley, Christine Norton and Anita Saltmarche for their substantial contributions to this endeavour. Without an educational grant from Pharmacia & Upjohn, and the personal sacrifice and professional commitment of all participants the P97 conference would have remained an idea in Athens. This Consensus Statement was first issued at the 1997 International Continence Society meeting in Yokohama, Japan. RETURN TO TOP OF PAGE A CLINICAL DEFINITION URINARY INCONTINENCE Since there are numerous definitions of Urinary Incontinence, it was agreed that the International Continence Society definition be adopted by the Conference. Urinary Incontinence 'is a condition in which involuntary urine loss is a social or hygienic problem and is objectively demonstrable'. However, the 'objectively demonstrable' criteria may require modification in large-scale epidemiological work. RETURN TO TOP OF PAGE B THE CONCEPTION OF PREVENTION While there are different models of prevention, the following definitions related to prevention were used as points for discussion. It was noted that these definitions are embedded in a disease model. PRIMARY PREVENTION Preventing disease from occurring by removing its causes. SECONDARY PREVENTION Detecting asymptomatic disease early and treating it to stop progression. TERTIARY PREVENTION Activities that prevent deterioration or reduce complications after a disease has declared itself. THE IMPAIRMENT-DISABILITY-HANDICAP MODEL Recognising that incontinence is not a disease but is a symptom or condition the panel felt it may be necessary to consider a prevention model similar to the Rehabilitation model of Impairment~Disability-Handicap. Using this model, impairment would be the underlying bladder or sphincter dysfunction (or dysfunction of the neurological control system at any level). Disability would be the consequent symptom of incontinence. The limitations imposed on the individual's quality of life are the handicap. Therefore, primary prevention would be aimed at preventing the underlying impairment from developing. Secondary prevention would be preventing the individual, despite an underlying predisposition, from becoming incontinent. Tertiary prevention would be preventing incontinence from worsening, or causing complications (such as skin problems) or limiting the impact of being incontinent upon the individual and those around them. QUALITY OF LIFE Quality of life was a recurring theme at the conference. Although the concept is frequently addressed in research, it is often not clearly defined. It was agreed that the outcome of any prevention strategy should be assessed not only in terms of bladder function, but also should incorporate the individual's perspective. Quality of life outcomes need to include overall benefits to both the individual and society as a whole. It was recognised that prevention programmes are likely to be costly. Consequently, future prevention research should consider a cost-benefit analysis. It was agreed that the focus of this meeting should be on primary and secondary prevention as treatment and containment are discussed and researched elsewhere. It was further agreed that some primary prevention measures, such as those aimed at preventing neurological disease or injury (with subsequent incontinence) were beyond the scope of this conference. RETURN TO TOP OF PAGE C HEALTHY BLADDER HABITS P97 participants agreed that the promotion of prevention is essential and therefore developed these recommendations. Drink Adequately: |
|
| Recognise that: |
|
| Relax: |
|
| Try to keep bowel movements regular: |
|
| Seek professional help when: |
|
| RETURN
TO TOP OF PAGE D INCONTINENCE PREVENTION BY AGE GROUP PREVENTION IN CHILDHOOD |
| Clinical
Evidence Indicates what is known about preventing incontinence. |
|
| Research
priorities Not in order of priority. |
|
| PREVENTION IN YOUNG ADULTS |
| Clinical
Evidence Indicates what is known about preventing incontinence. |
|
| Research
priorities Not in order of priority. |
|
| PREVENTION
IN THE MIDDLE YEARS Clinical Evidence Indicates what is known about preventing incontinence. |
|
| Research
priorities Not in order of priority. |
|
| PREVENTION
IN HEALTHY OLDER ADULTS Clinical Evidence Indicates what is known about preventing incontinence. Investigated Risk Factors |
|
| Current research has not proven the importance of: |
|
| Research
priorities Not in order of priority. |
|
| PREVENTION
IN FRAIL OLDER ADULTS Clinical Evidence Indicates what is known about preventing incontinence. |
|
| Investigated associations include: |
|
| Research
priorities Not in order of priority. |
|
| RETURN
TO TOP OF PAGE |
| E
PROMOTING PREVENTION EDUCATION BY TARGET GROUP GENERAL PUBLIC The panel agreed that extensive education across the following target groups was necessary to promote prevention of incontinence. |
|
| HEALTH
PROFESSIONALS / RESEARCHERS Health professionals would be well advised to incorporate this knowledge into their everyday clinical practice. Patients and the general public could benefit from the dissemination of this knowledge. We have identified many deficiencies in existing research data. There is a need to increase the quality of prevention research, to standardize terminology, and utilize prospective cohort designs for research. These improvements are necessary despite being both costly and time-consuming. Standardization of data acquisition, diagnostic methods, interviews, interventions and measurement are essential. This standardisation would be best coordinated through the International Continence Society. It is important that researchers fully understand the implications of different study designs, and what can and cannot be determined about causative links. OTHER GROUPS Government bodies, especially Health Departments, but also others including Departments of Education, Employment etc. Health insurance companies or other health funders as appropriate in each country. National organizations and societies whose members or target audience may have continence risks (such as organizations of people with neurological diseases), or whose members may have health care responsibilities for potentially incontinent people (doctors, nurses and other health professionals). Each group will need a message specifically targeted to their own areas of interest, to ensure they take an active role in prevention. International organizations such as the International Continence Society (ICS), World Health Organization (WHO), International Consultation on Incontinence (Monaco 1998), and other health related organizations all need to work together to ensure a strong and consistent message is disseminated. Industry. Companies which produce products to treat or manage incontinence should be encouraged to use their considerable communication channels to promote the prevention of incontinence. THE FUTURE PROMOTING CONTINENCE The challenge for professionals will be the integration of this clinical evidence into practice and promoting and implementing these prevention strategies. More research is needed to supplement these initiatives. This Consensus Statement has been published on behalf of all who would benefit from the implementation of PREVENTION strategies. RETURN TO TOP OF PAGE |
|
CONFERENCE PARTICIPANTS (cc) Conference Co-Chairs (pc) Panel Chair (pm) Panel Members (s) Speakers (pl) Planning Committee Ted Arnold MD Associate Professor Department of Urology Christchurch Hospital Christchurch New Zealand Kari Bo PhD, PT Associate Professor Norwegian University of Sports & Physical Education Oslo, Norway Linda Brubaker MD (s) Associate Professor Department of Obstetrics & Gynecology Rush Medical College; Director - Urogynecology & Reconstructive Pelvic Surgery Rush Presbyterian St. Luke's Medical Center Chicago, Illinois, U.S.A. Richard Bump MD (s) Associate Professor and Chief Division of Gynecologic Specialties Duke University Medical Center Durham, North Carolina, U.S.A. Kathryn Burgio PhD (s) Director - Continence Program Division of Gerontology & Geriatric Medicine and Center for Aging University of Alabama at Birmingham Birmingham,Alabama, U.S.A. Alan Cottenden PhD (pc) Lecturer in Medical Physics University College London London, England Ananias Diokno MD (s, pl) Chief - Department of Urology William Beaumont Hospital Royal Oak Michigan, U.S.A. Peter Dwyer MD Associate Professor Department of Obstetrics & Gynaecology Fitzroy, Australia David Fonda MD (s) Associate Professor Director, Aged Care Service Head, Caulfield Continence Service Caulfield General Medical Centre Caulfield, Australia Clare Fowler MD (s) Consultant in UroNeurology National Hospital for Neurology and Neurosurgery London, England Cheryle B. Gartley (cc, pl, pm) President & Founder The Simon Foundation for Continence Wilmette, Illinois, U.S.A. Derek Griffiths PhD (pm) Urodynamics & Northern Alberta Continence Services Misericordia Community Hospital & Health Centre Edmonton, Alberta, Canada Francine Grodstein ScD (s, pm) Instructor of Medicine, Channing Laboratory Department of Medicine Brigham and Women's Hospital Harvard Medical School Boston, Massachusetts, U.S.A. Sender Herschorn MD Head, Division of Urology Sunnybrook Health Science Centre; Associate Professor University of Toronto Toronto, Ontario, Canada Rudi Janknegt MD Professor, Department of Urology University of Maastricht Maastricht, Netherlands Steven Kaplan MD (s) Professor and Vice-chairman Department of Urology College of Physicians and Surgeons Columbia University New York, New York, U.S.A. Ruth Kirschner-Hermanns MD (s) Research Fellow Gerontology Division Brigham and Women's Hospital Harvard Medical School Boston, Massachusetts, U.S.A. Jo Laycock PhD, PT The Culgaith Clinic Culgaith, England Gunnar Lose MD Chief, Department of Obstetrics & Gynaecology Glostrup, Denmark Peter Lim MD President Society of Continence (Singapore); Division of Urology Toa Payoh Hospital Toa Payoh, Singapore Helmut Madersbacher MD Associate Professor of Urology Head of the Neuro-urology Unit University Hospital Innsbruck, Austria Reverend Colin McLean (pm) Chairman Incontact London, England Richard Millard MD Associate Professor University of New South Wales; Department of Urology The Prince Henry Hospital Sydney, Australia Katherine Moore PhD Assistant Professor Faculty of Nursing University of Alberta Edmonton, Alberta, Canada Kaoru Nishimura President Japan Continence Action Society Tokyo, Japan Christine Norton MA, RN (cc, pl, pm) Nurse Specialist - Continence Northwick Park & St. Mark's Hospital Middlesex, England Peggy Norton MD (s, pl) Associate Professor Head - Uro-gynecology & Pelvic Reconstructive Surgery Salt Lake City, Utah, U.S.A. Leroy Nyberg Jr. MD (pm) Director Urology Programs NIH/NIDDK/KUH Bethesda, Maryland, U.S.A. David Pollock BA Director The Continence Foundation London, England Neil Resnick MD (pl) Chief of Gerontology Brigham and Women's Hospital; Associate Professor Harvard Medical School Boston, Massachusetts, U.S.A. Brenda Roe PhD, RN (pm) Professor Institute of Human Aging University of Liverpool Liverpool, England Ron Rozensky PhD (pl, pm) Professor, Psychiatry & Behavioural Sciences Northwestern University Medical School; Associate Chairperson Department of Psychiatry Evanston Hospital Evanston, Illinois, U.S.A. Anita Saltmarche MHSc, RN (cc, s, pl) President - Canadian Continence Foundation; Clinical Associate - Faculty of Nursing University of Toronto; President - HealthCare Associates Toronto, Ontario, Canada Nigel Smith MD Senior Clinical Research Fellow Honorary Consultant Faculty of Medicine University of Leicester Paul Smith PhD (s) Clinical Psychologist North Tyneside Health Care NHS Trust North Tyneside, England Stuart Stanton MD Consultant - Urogynaecology St. George's Hospital Urogynaecology Unit; Chairman - The Continence Foundation London, England Eboo Versi MD Department of Gynecology & Obstetrics Brigham & Women's Hospital Harvard Medical School Boston, Massachusetts, U.S.A. Thelma J. Wells PhD, RN (pm) Helen Denne Schulte Nursing Professor University of Wisconsin Madison, Wisconson, U.S.A. Don Wilson MD Associate Professor Department of Obstetrics & Gynaecology University of Otago Dunedin, New Zealand RETURN TO TOP OF PAGE |
[Revised 4 April 2001]